SCHEMBL7040190

SCHEMBL7040190

CC(=O)Nc1cccc(-c2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)c(C(=O)O)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.56
PPARD Q03181 4/20 0.56
NR1H4 Q96RI1 4/20 0.56
RXFP1 Q9HBX9 6/20 0.55
AKR1C3 P42330 2/20 0.54
AKR1C2 P52895 2/20 0.54
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
IGF2BP2 Q9Y6M1 1/20 0.53
MPO P05164 1/20 0.53
PPARA Q07869 3/20 0.51
SERPINE1 P05121 1/20 0.50
ACLY P53396 1/20 0.50
HDAC1 Q13547 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL7042124 0.89 RXFP1 (0.53) PPARGPPARDNR1H4RXFP1MEN1
SCHEMBL7039689 0.83 MAPT (0.55) PPARGPPARDNR1H4RXFP1MEN1
SCHEMBL3991239 0.82 KDM1A (0.55) RXFP1AKR1C3AKR1C2NPC1MAPT
SCHEMBL7038142 0.81 IGF2BP2 (0.54) PPARGPPARDNR1H4NPC1RAB9A
SCHEMBL2267918 0.77 ACLY (0.74) PPARGPPARDNR1H4NPC1RAB9A
SCHEMBL7038115 0.76 IGF2BP2 (0.50) PPARGPPARDNR1H4AKR1C3AKR1C2
SCHEMBL7039302 0.76 PPARG (0.61) PPARGMEN1NPC1MAPTRAB9A
SCHEMBL16496601 0.76 SERPINE1 (0.75) PPARGNR1H4AKR1C3AKR1C2MEN1
SCHEMBL7038149 0.76 IGF2BP2 (0.49) PPARGPPARDNR1H4AKR1C3AKR1C2
SCHEMBL5944018 0.75 PARP1 (0.67) RXFP1MEN1NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US claimed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073862-A1 Compounds PPARG, PPARA, PPARD PPARG 1/4885PPARD 3/4885NR1H4 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.